ABSTRACT
Assessing a potential resurgence of an epidemic outbreak with certainty is as important as challenging. The low number of infectious individuals after a long regression, and the randomness associated with it, makes it difficult to ascertain whether the infectious population is growing or just fluctuating. We have developed an approach to compute confidence intervals for the switching time from decay to growth and to compute the corresponding supra-location aggregated quantities to increase the precision of the determination. We estimated the aggregate prevalence over time for Europe and the Northeast United States to characterize the COVID-19 second surge in these regions during year 2020. We find a starting date as early as July 3 (95% Confidence Interval (CI): July 1– July 6) for Europe and August 19 (95% CI: August 16 – August 23) for the Northeast; subsequent infectious populations that, as of December 31 have always increased or remained stagnant; and the resurgences being the collective effect of each overall region with no location dominating the regional dynamics by itself.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
J.M.G.V. acknowledges support from Ministerio de Ciencia e Innovacion under grant PGC2018-101282-B-I00 (MCI/AEI/FEDER, UE). L.S. acknowledges support from the University of California, Davis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Details for accessing the data sources are provided in the manuscript.
